Who are 5ARI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Saw Palmetto - first 24 weeks, tamsulosin and/or dutasteride, Saw Palmetto - weeks 24 - 48, Avodart, Propecia.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/5ari.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

5ARI — Competitive Intelligence Brief

5ARI (5ARI) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-alpha-reductase inhibitor. Area: Urology.

phase 2 5-alpha-reductase inhibitor 5-alpha-reductase Urology Small molecule Live · refreshed every 30 min

Target snapshot

5ARI (5ARI) — GlaxoSmithKline. 5-alpha-reductase inhibitor

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
5ARI TARGET	5ARI	GlaxoSmithKline	phase 2	5-alpha-reductase inhibitor	5-alpha-reductase
Saw Palmetto - first 24 weeks	Saw Palmetto - first 24 weeks	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
tamsulosin and/or dutasteride	tamsulosin and/or dutasteride	Case Comprehensive Cancer Center	phase 3	Alpha-1 adrenergic receptor antagonist and 5-alpha-reductase inhibitor	Alpha-1 adrenergic receptor and 5-alpha-reductase
Saw Palmetto - weeks 24 - 48	Saw Palmetto - weeks 24 - 48	University of Alabama at Birmingham	phase 3	Phytotherapeutic	5-alpha-reductase
Avodart	dutasteride	GSK (GlaxoSmithKline)	marketed	5-alpha-reductase inhibitor (dual)	3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1	2001-11-20
Propecia	finasteride	Merck & Co.	marketed	5-alpha-reductase inhibitor	3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9	1992-06-19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-alpha-reductase inhibitor class)

GlaxoSmithKline · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 5ARI — Competitive Intelligence Brief. https://druglandscape.com/ci/5ari. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab